A Phase Ⅱ Clinical Trial of SYH2072 Tablets in Participants With Primary Aldosteronism

Inclusion Criteria:

1. Aged 18 years or older; male or female.
2. Documented diagnosis of primary aldosteronism (PA) before screening.
3. Receiving stable antihypertensive therapy.
4. Willing to discontinue mineralocorticoid receptor antagonists (MRA) or potassium-sparing diuretics.
5. Mean seated office systolic blood pressure (SBP) ≥140 mmHg and <180 mmHg, and mean seated office diastolic blood pressure (DBP) <110 mmHg before randomization.
6. Medication compliance of background antihypertensive therapy and placebo within 80%-120% during the run-in period.
7. Voluntary participation in the study, with signed informed consent form.

Exclusion Criteria:

1. Night shift workers.
2. Known secondary causes of hypertension other than PA.
3. Hypotension.
4. Known hypersensitivity or allergic constitution.
5. History of adrenal surgery, renal denervation, or similar procedures.
6. History of adrenal insufficiency.
7. Poorly controlled blood glucose, or GLP-1 receptor agonist not maintained at a stable dose for at least 4 weeks.
8. Poorly controlled thyroid disease.
9. Severe cardiovascular or cerebrovascular events within 6 months before screening.
10. Severe arrhythmia within 6 months before screening.
11. Severe heart failure within 6 months before screening.
12. Major surgery within 6 months before screening.
13. Severe gastrointestinal disease or history of gastrointestinal surgery.
14. Clinically significant laboratory abnormalities.
15. History of malignancy within 5 years.
16. History of drug abuse within 5 years.
17. Female participants who are pregnant, breastfeeding, or with a positive pregnancy test.
18. Use of strong CYP3A4 inhibitors or strong CYP3A4 inducers within 4 weeks before screening.
19. Participation in any drug or device clinical trial within 3 months before screening.
20. Regular alcohol consumption within 90 days before screening.
21. Any other reason that, in the opinion of the investigator, may prevent the participant from completing the study, or any condition for which the investigator considers enrollment inappropriate.